{
    "data": [
        {
            "id": "2775515",
            "type": "article",
            "attributes": {
                "publishOn": "2014-12-23T07:58:40-05:00",
                "isLockedPro": false,
                "commentCount": 16,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Competes On Price",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20694",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2775515-abbvie-competes-on-price"
            }
        },
        {
            "id": "2775355",
            "type": "article",
            "attributes": {
                "publishOn": "2014-12-23T07:07:02-05:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Competes On Price",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20694",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2775355-abbvie-competes-on-price"
            }
        },
        {
            "id": "2767355",
            "type": "article",
            "attributes": {
                "publishOn": "2014-12-19T19:55:07-05:00",
                "isLockedPro": false,
                "commentCount": 126,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "While Gilead's Profits Soar, Uncertainty Reigns Supreme At AbbVie",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "72015",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2767355-while-gileads-profits-soar-uncertainty-reigns-supreme-at-abbvie"
            }
        },
        {
            "id": "2714345",
            "type": "article",
            "attributes": {
                "publishOn": "2014-11-26T12:57:11-05:00",
                "isLockedPro": false,
                "commentCount": 18,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Dividend Aristocrats In Focus Part 45: AbbVie",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "63883",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2714345-dividend-aristocrats-in-focus-part-45-abbvie"
            }
        },
        {
            "id": "2681625",
            "type": "article",
            "attributes": {
                "publishOn": "2014-11-14T02:55:09-05:00",
                "isLockedPro": false,
                "commentCount": 118,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "If Gilead Has The Ace, Is AbbVie Holding The Big Joker?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "144916",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2681625-if-gilead-has-the-ace-is-abbvie-holding-the-big-joker"
            }
        },
        {
            "id": "2631165",
            "type": "article",
            "attributes": {
                "publishOn": "2014-11-03T11:00:21-05:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbvie Inc. Trading At A Deep Discount, But With Risks",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21835",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2631165-abbvie-inc-trading-at-a-deep-discount-but-with-risks"
            }
        },
        {
            "id": "2607215",
            "type": "article",
            "attributes": {
                "publishOn": "2014-10-28T17:56:37-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why The AbbVie/Shire Deal Collapsed",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "75445",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2607215-why-the-abbvie-shire-deal-collapsed"
            }
        },
        {
            "id": "2582915",
            "type": "article",
            "attributes": {
                "publishOn": "2014-10-22T09:11:41-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Update: AbbVie's Share Repurchase Plan And Dividend Hike Makes It Even More Attractive",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "44981",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2582915-update-abbvies-share-repurchase-plan-and-dividend-hike-makes-it-even-more-attractive"
            }
        },
        {
            "id": "2564825",
            "type": "article",
            "attributes": {
                "publishOn": "2014-10-15T17:06:44-04:00",
                "isLockedPro": false,
                "commentCount": 21,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Does Not Stand To Lose Much If It Drops Shire Deal Now",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "47291",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2564825-abbvie-does-not-stand-to-lose-much-if-it-drops-shire-deal-now"
            }
        },
        {
            "id": "2564815",
            "type": "article",
            "attributes": {
                "publishOn": "2014-10-15T17:05:34-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie-Shire Deal Not Quite Dead Yet",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "51092",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "143129",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/2564815-abbvie-shire-deal-not-quite-dead-yet"
            }
        },
        {
            "id": "2457895",
            "type": "article",
            "attributes": {
                "publishOn": "2014-08-28T13:59:02-04:00",
                "isLockedPro": false,
                "commentCount": 31,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Growth Story Or Patent Expiration Nightmare?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "63883",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2457895-abbvie-growth-story-or-patent-expiration-nightmare"
            }
        },
        {
            "id": "2419405",
            "type": "article",
            "attributes": {
                "publishOn": "2014-08-13T13:38:46-04:00",
                "isLockedPro": false,
                "commentCount": 31,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie's Acquisition Of Shire: Skepticism Creates Buying Opportunity",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "61291",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "138524",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2419405-abbvies-acquisition-of-shire-skepticism-creates-buying-opportunity"
            }
        },
        {
            "id": "2383595",
            "type": "article",
            "attributes": {
                "publishOn": "2014-08-05T15:05:10-04:00",
                "isLockedPro": false,
                "commentCount": 12,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Is AbbVie A Long-Term Buy?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "57152",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "137909",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2383595-is-abbvie-a-long-term-buy"
            }
        },
        {
            "id": "2369905",
            "type": "article",
            "attributes": {
                "publishOn": "2014-08-01T10:05:35-04:00",
                "isLockedPro": false,
                "commentCount": 23,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Shareholders Prevail",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21136",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "137649",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2369905-abbvie-shareholders-prevail"
            }
        },
        {
            "id": "2345085",
            "type": "article",
            "attributes": {
                "publishOn": "2014-07-26T03:05:48-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Market Ignores AbbVie's Impressive Sales Due To Reliance On Humira",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "137223",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2345085-market-ignores-abbvies-impressive-sales-due-to-reliance-on-humira"
            }
        },
        {
            "id": "2334265",
            "type": "article",
            "attributes": {
                "publishOn": "2014-07-23T14:44:28-04:00",
                "isLockedPro": false,
                "commentCount": 109,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Surprise: The Real Costs Of Inversions Are Paid By Ordinary Shareholders",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21544",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2334265-surprise-the-real-costs-of-inversions-are-paid-by-ordinary-shareholders"
            }
        },
        {
            "id": "2326055",
            "type": "article",
            "attributes": {
                "publishOn": "2014-07-21T09:33:55-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Gets Its 'Tax Break' In Shire",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24805",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "136931",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2326055-abbvie-gets-its-tax-break-in-shire"
            }
        },
        {
            "id": "2311875",
            "type": "article",
            "attributes": {
                "publishOn": "2014-07-13T01:58:18-04:00",
                "isLockedPro": false,
                "commentCount": 13,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Where Are We At With AbbVie's Acquisition Of Shire?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25341",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "136531",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2311875-where-are-we-at-with-abbvies-acquisition-of-shire"
            }
        },
        {
            "id": "2298705",
            "type": "article",
            "attributes": {
                "publishOn": "2014-07-03T11:38:34-04:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Barclays Is Late To Upgrade, Using Highly Favorable Assumptions",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2298705-abbvie-barclays-is-late-to-upgrade-using-highly-favorable-assumptions"
            }
        },
        {
            "id": "2284753",
            "type": "article",
            "attributes": {
                "publishOn": "2014-06-24T18:25:41-04:00",
                "isLockedPro": false,
                "commentCount": 33,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why Investors Should Sell AbbVie And Buy Gilead Sciences",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "54222",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2284753-why-investors-should-sell-abbvie-and-buy-gilead-sciences"
            }
        },
        {
            "id": "2278503",
            "type": "article",
            "attributes": {
                "publishOn": "2014-06-20T07:34:34-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie - Attempt To Acquire Shire Is Driven By Opportunistic Tax Synergies",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "135522",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2278503-abbvie-attempt-to-acquire-shire-is-driven-by-opportunistic-tax-synergies"
            }
        },
        {
            "id": "2229993",
            "type": "article",
            "attributes": {
                "publishOn": "2014-05-21T07:35:33-04:00",
                "isLockedPro": false,
                "commentCount": 12,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Invest In AbbVie's New Blockbuster Drug",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56732",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "134143",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2229993-invest-in-abbvies-new-blockbuster-drug"
            }
        },
        {
            "id": "2217203",
            "type": "article",
            "attributes": {
                "publishOn": "2014-05-14T10:23:22-04:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Or AbbVie - Which One Is Right For Your Dividend Income Dollars",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "64213",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2217203-abbott-or-abbvie-which-one-is-right-for-your-dividend-income-dollars"
            }
        },
        {
            "id": "2214753",
            "type": "article",
            "attributes": {
                "publishOn": "2014-05-13T13:22:19-04:00",
                "isLockedPro": false,
                "commentCount": 34,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "The Best Dividend Growers, Part 7: Pfizer And AbbVie",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "52212",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2214753-the-best-dividend-growers-part-7-pfizer-and-abbvie"
            }
        },
        {
            "id": "2127643",
            "type": "article",
            "attributes": {
                "publishOn": "2014-04-06T05:01:44-04:00",
                "isLockedPro": false,
                "commentCount": 23,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie - Strong Product Pipeline Is Defining Its Future",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56732",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "131998",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2127643-abbvie-strong-product-pipeline-is-defining-its-future"
            }
        },
        {
            "id": "2099283",
            "type": "article",
            "attributes": {
                "publishOn": "2014-03-20T05:41:56-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbvie Inc. Dividend Stock Analysis",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21835",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2099283-abbvie-inc-dividend-stock-analysis"
            }
        },
        {
            "id": "2054263",
            "type": "article",
            "attributes": {
                "publishOn": "2014-02-27T11:46:20-05:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie: Attractive For Both Dividend And Growth Investors",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "44981",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2054263-abbvie-attractive-for-both-dividend-and-growth-investors"
            }
        },
        {
            "id": "2007521",
            "type": "article",
            "attributes": {
                "publishOn": "2014-02-10T07:47:28-05:00",
                "isLockedPro": false,
                "commentCount": 24,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "The Hep C Race Is Heating Up: AbbVie Vs. Gilead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31361",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "128962",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2007521-the-hep-c-race-is-heating-up-abbvie-vs-gilead"
            }
        },
        {
            "id": "2005011",
            "type": "article",
            "attributes": {
                "publishOn": "2014-02-07T15:42:29-05:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie's Testosterone: Impact Of Health Concerns",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23478",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2005011-abbvies-testosterone-impact-of-health-concerns"
            }
        },
        {
            "id": "1985921",
            "type": "article",
            "attributes": {
                "publishOn": "2014-01-31T15:24:46-05:00",
                "isLockedPro": false,
                "commentCount": 12,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "ModernGraham Annual Valuation Of AbbVie",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23471",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "92371",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1985921-moderngraham-annual-valuation-of-abbvie"
            }
        }
    ]
}